Department of Radiation Oncology, Allegheny General Hospital, Pittsburgh, Pa.
Oncora Medical, Philadelphia, Pa.
J Thorac Cardiovasc Surg. 2019 Feb;157(2):758-766.e1. doi: 10.1016/j.jtcvs.2018.10.039. Epub 2018 Oct 22.
There are 2 main treatment paradigms recognized by the National Comprehensive Cancer Network for resectable malignant pleural mesothelioma (MPM): induction chemotherapy followed by resection (IC/R), and up-front resection with postoperative chemotherapy (R/PC). These paradigms are being compared in an accruing randomized phase II trial. In the absence of such completed trials, in this study we evaluated overall survival (OS) and postoperative outcomes of IC/R and R/PC.
The National Cancer Database was queried for newly diagnosed epithelioid/biphasic MPM. Metastatic, node-positive, and/or cT4 disease was excluded, along with nondefinitive surgery and lack of chemotherapy. Multivariable logistic regression ascertained factors independently associated with induction chemotherapy delivery. Kaplan-Meier analysis was used to evaluate OS between cohorts; multivariable Cox proportional hazards modeling was used to assess factors associated with OS. Survival was also evaluated between propensity-matched populations. Last, postoperative outcomes were assessed between groups.
Overall, 361 patients (182 IC/R, 179 R/PC) were analyzed. Temporal trends revealed that IC/R is decreasing over time. Survival of the IC/R cohort was similar to that of R/PC patients (20.9 vs 21.7 months; P = .500); this persisted after propensity matching (20.8 vs 22.0 months; P = .270). However, patients who underwent IC/R experienced longer postoperative hospitalization (median 7 days vs 6 days; P = .001) and higher 30-day mortality (3.3% vs 0%; P = .020).
To our knowledge, this is the only comparative investigation of the 2 major management paradigms of operable MPM. IC/R regimens are decreasing over time in the United States. Although associated with survival similar to R/PC, IC/R might be associated with worse postoperative outcomes. Careful induction chemotherapy patient selection is thus highly recommended.
美国国家综合癌症网络(National Comprehensive Cancer Network)针对可切除恶性胸膜间皮瘤(malignant pleural mesothelioma,MPM)认可了 2 种主要的治疗模式:诱导化疗后切除(induction chemotherapy followed by resection,IC/R)和初始切除后化疗(resection with postoperative chemotherapy,R/PC)。正在进行一项入组的随机 2 期试验比较这两种模式。在缺乏已完成试验的情况下,本研究评估了 IC/R 和 R/PC 的总生存(overall survival,OS)和术后结果。
国家癌症数据库(National Cancer Database)中检索新诊断为上皮样/双相性 MPM 的患者。排除转移性、淋巴结阳性和/或 cT4 疾病、非确定性手术和缺乏化疗的患者。多变量逻辑回归确定了与诱导化疗实施相关的独立因素。采用 Kaplan-Meier 分析评估队列间 OS;采用多变量 Cox 比例风险模型评估与 OS 相关的因素。在倾向匹配人群中也评估了生存情况。最后,评估了两组之间的术后结果。
共分析了 361 例患者(182 例 IC/R,179 例 R/PC)。时间趋势显示,IC/R 随时间推移呈下降趋势。IC/R 组的生存情况与 R/PC 患者相似(20.9 与 21.7 个月;P=0.500);在倾向匹配后仍然如此(20.8 与 22.0 个月;P=0.270)。然而,接受 IC/R 的患者术后住院时间更长(中位数 7 天与 6 天;P=0.001),30 天死亡率更高(3.3%与 0%;P=0.020)。
据我们所知,这是对可切除 MPM 两种主要治疗模式的唯一比较研究。在美国,IC/R 方案的应用随时间推移而减少。尽管与 R/PC 生存相似,但 IC/R 可能与更差的术后结果相关。因此,强烈推荐对接受诱导化疗的患者进行仔细选择。